.png){kind=logo}
Danaher plans to launch its first AI-powered autonomous research lab in early 2027. The life sciences company aims to speed drug discovery through AI, robotics, and connected laboratory technologies. The lab will operate at scale from an Abcam facility and develop custom antibodies and molecular tools. Danaher expects the system to accelerate molecule discovery by up to 8 times. It also targets a tenfold increase in annual target-binding molecule generation.
The Danaher AI research lab will connect technologies from several operating companies into one workflow. The system will use AI to design molecules that bind specific biological targets with greater precision.
Robotics will then build and test those designs before returning results to the AI model. Each testing cycle will help improve the next round of molecular designs.
The approach creates a continuous design, make, test, and learn cycle for laboratory research. Danaher expects this model to move researchers from an initial idea toward validated reagents much faster. The company also expects annual reagent production to rise from tens to hundreds as the lab scales.
JC Gutierrez-Ramos, Danaher's chief science officer, said the faster cycle can give scientists more time for complex challenges. Human researchers will continue making key scientific decisions while automation handles repetitive laboratory processes. The model therefore combines machine speed with human judgment rather than replacing scientific expertise.
The lab will bring together capabilities from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices. Danaher is also working with Automata on robotic orchestration and laboratory automation for the connected system.
The project forms part of a wider Danaher program focused on smart laboratory instruments. These systems aim to generate AI-ready data and connect equipment through integrated research workflows. Danaher sees autonomous labs as a way to make scientific experimentation faster, more consistent, and easier to scale.
For drug discovery, the larger shift could come from faster experimental feedback. Researchers could evaluate more molecular designs while spending less time on repetitive laboratory tasks. The result could help expand target exploration and shorten early research cycles without removing scientific oversight.
Also Read: AstraZeneca Bets USD 2 Billion on Summit’s Experimental Cancer Drug
